Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDCAN GC02
- Development stage
- Phase 3
- Lead developer
- Medcan Australia
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
MEDCAN GC02 is an orally administered medicinal cannabis capsule developed by Medcan Australia. It is formulated as a fixed-dose combination containing 5 mg of delta-9-tetrahydrocannabinol (THC) and 8 mg of cannabidiol (CBD). As a cannabinoid-based therapeutic, it exerts its effects primarily through the modulation of the endocannabinoid system, specifically targeting cannabinoid receptors CB1 and CB2. In Australia, MEDCAN GC02 is not registered on the Australian Register of Therapeutic Goods (ARTG) but is available to patients via the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category A/B) and the Authorised Prescriber Scheme.
- Brand names
- MEDCAN GC02
- Other names
- cannabidiol + tetrahydrocannabinoltetrahydrocannabinol + cannabidiol
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on MEDCAN GC02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDCAN GC02.